Joshua Pinto - 28 May 2025 Form 4 Insider Report for Neumora Therapeutics, Inc. (NMRA)

Role
President
Signature
/s/ Michael Milligan, as Attorney-in-Fact for Joshua Pinto
Issuer symbol
NMRA
Transactions as of
28 May 2025
Net transactions value
$0
Form type
4
Filing time
30 May 2025, 18:25:19 UTC
Previous filing
23 May 2025
Next filing
13 Nov 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Pinto Joshua President C/O NEUMORA THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN /s/ Michael Milligan, as Attorney-in-Fact for Joshua Pinto 30 May 2025 0001992595

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NMRA Stock Option (Right to Buy) Disposed to Issuer -223,034 -100% 0 28 May 2025 Common Stock 223,034 $1.69 Direct F1, F2
transaction NMRA Stock Option (Right to Buy) Disposed to Issuer -270,828 -100% 0 28 May 2025 Common Stock 270,828 $1.69 Direct F2, F3
transaction NMRA Stock Option (Right to Buy) Disposed to Issuer -223,034 -100% 0 28 May 2025 Common Stock 223,034 $1.69 Direct F2, F4
transaction NMRA Stock Option (Right to Buy) Disposed to Issuer -720,084 -100% 0 28 May 2025 Common Stock 720,084 $1.69 Direct F2, F5
transaction NMRA Stock Option (Right to Buy) Disposed to Issuer -127,448 -100% 0 28 May 2025 Common Stock 127,448 $1.69 Direct F2, F6
transaction NMRA Stock Option (Right to Buy) Disposed to Issuer -170,000 -100% 0 28 May 2025 Common Stock 170,000 $1.69 Direct F2, F7
transaction NMRA Stock Option (Right to Buy) Disposed to Issuer -3,000,000 -100% 0 28 May 2025 Common Stock 3,000,000 $1.69 Direct F2, F8
transaction NMRA Stock Option (Right to Buy) Award +223,034 223,034 28 May 2025 Common Stock 223,034 $0.7200 Direct F1, F2, F9
transaction NMRA Stock Option (Right to Buy) Award +270,828 270,828 28 May 2025 Common Stock 270,828 $0.7200 Direct F2, F3, F9
transaction NMRA Stock Option (Right to Buy) Award +223,034 223,034 28 May 2025 Common Stock 223,034 $0.7200 Direct F2, F4, F9
transaction NMRA Stock Option (Right to Buy) Award +720,084 720,084 28 May 2025 Common Stock 720,084 $0.7200 Direct F2, F5, F9
transaction NMRA Stock Option (Right to Buy) Award +127,448 127,448 28 May 2025 Common Stock 127,448 $0.7200 Direct F2, F6, F9
transaction NMRA Stock Option (Right to Buy) Award +170,000 170,000 28 May 2025 Common Stock 170,000 $0.7200 Direct F2, F7, F9
transaction NMRA Stock Option (Right to Buy) Award +3,000,000 3,000,000 28 May 2025 Common Stock 3,000,000 $0.7200 Direct F2, F8, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/36th of the shares subject to the option vest on each monthly anniversary measured from June 30, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date.
F2 On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 9, all other terms of the option remain unchanged.
F3 The option is early exercisable. 1/36th of the shares subject to the option vest on each monthly anniversary measured from June 1, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested on the third anniversary of the Vesting Commencement Date.
F4 The performance-based stock option becomes exercisable in two tranches upon the achievement of specified stock price milestones. Each tranche shall vest in 24 equal monthly installments measured from the stock price achievement date.
F5 25% of the shares subject to the option vest on the first anniversary measured from February 1, 2022 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
F6 25% of the shares subject to the option vest on the first anniversary measured from June 30, 2023 (the "Vesting Commencement Date'), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
F7 25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
F8 25% of the shares subject to the option vest on the first anniversary measured from February 13, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
F9 On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026.